These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 31340106)

  • 1. Verubecestat for Prodromal Alzheimer's Disease. Reply.
    Kennedy ME; Egan MF
    N Engl J Med; 2019 Jul; 381(4):389. PubMed ID: 31340106
    [No Abstract]   [Full Text] [Related]  

  • 2. Verubecestat for Prodromal Alzheimer's Disease.
    Li S; Liu L; Selkoe D
    N Engl J Med; 2019 Jul; 381(4):388. PubMed ID: 31340105
    [No Abstract]   [Full Text] [Related]  

  • 3. Lessons that can be learnt from the failure of verubecestat in Alzheimer's disease.
    Doggrell SA
    Expert Opin Pharmacother; 2019 Dec; 20(17):2095-2099. PubMed ID: 31423903
    [No Abstract]   [Full Text] [Related]  

  • 4. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
    Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
    J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Merck ends trial of potential Alzheimer's drug verubecestat.
    Hawkes N
    BMJ; 2017 Feb; 356():j845. PubMed ID: 28202490
    [No Abstract]   [Full Text] [Related]  

  • 6. Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease.
    Thaisrivongs DA; Miller SP; Molinaro C; Chen Q; Song ZJ; Tan L; Chen L; Chen W; Lekhal A; Pulicare SK; Xu Y
    Org Lett; 2016 Nov; 18(22):5780-5783. PubMed ID: 27934506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease.
    Scott JD; Li SW; Brunskill AP; Chen X; Cox K; Cumming JN; Forman M; Gilbert EJ; Hodgson RA; Hyde LA; Jiang Q; Iserloh U; Kazakevich I; Kuvelkar R; Mei H; Meredith J; Misiaszek J; Orth P; Rossiter LM; Slater M; Stone J; Strickland CO; Voigt JH; Wang G; Wang H; Wu Y; Greenlee WJ; Parker EM; Kennedy ME; Stamford AW
    J Med Chem; 2016 Dec; 59(23):10435-10450. PubMed ID: 27933948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease.
    Wessels AM; Lines C; Stern RA; Kost J; Voss T; Mozley LH; Furtek C; Mukai Y; Aisen PS; Cummings JL; Tariot PN; Vellas B; Dupre N; Randolph C; Michelson D; Andersen SW; Shering C; Sims JR; Egan MF
    Alzheimers Dement; 2020 Nov; 16(11):1483-1492. PubMed ID: 33049114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease.
    Henley D; Raghavan N; Sperling R; Aisen P; Raman R; Romano G
    N Engl J Med; 2019 Apr; 380(15):1483-1485. PubMed ID: 30970197
    [No Abstract]   [Full Text] [Related]  

  • 10. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.
    Kennedy ME; Stamford AW; Chen X; Cox K; Cumming JN; Dockendorf MF; Egan M; Ereshefsky L; Hodgson RA; Hyde LA; Jhee S; Kleijn HJ; Kuvelkar R; Li W; Mattson BA; Mei H; Palcza J; Scott JD; Tanen M; Troyer MD; Tseng JL; Stone JA; Parker EM; Forman MS
    Sci Transl Med; 2016 Nov; 8(363):363ra150. PubMed ID: 27807285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrocyclic glycopeptide chiral selectors bonded to core-shell particles enables enantiopurity analysis of the entire verubecestat synthetic route.
    Barhate CL; Lopez DA; Makarov AA; Bu X; Morris WJ; Lekhal A; Hartman R; Armstrong DW; Regalado EL
    J Chromatogr A; 2018 Mar; 1539():87-92. PubMed ID: 29397980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Next Generation Synthesis of BACE1 Inhibitor Verubecestat (MK-8931).
    Thaisrivongs DA; Morris WJ; Tan L; Song ZJ; Lyons TW; Waldman JH; Naber JR; Chen W; Chen L; Zhang B; Yang J
    Org Lett; 2018 Mar; 20(6):1568-1571. PubMed ID: 29481097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.
    Panza F; Seripa D; Solfrizzi V; Imbimbo BP; Lozupone M; Leo A; Sardone R; Gagliardi G; Lofano L; Creanza BC; Bisceglia P; Daniele A; Bellomo A; Greco A; Logroscino G
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):377-391. PubMed ID: 27678025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lowering of Amyloid-Beta by β-Secretase Inhibitors - Some Informative Failures.
    Knopman DS
    N Engl J Med; 2019 Apr; 380(15):1476-1478. PubMed ID: 30970194
    [No Abstract]   [Full Text] [Related]  

  • 15. BACE inhibitor bust in Alzheimer trial.
    Mullard A
    Nat Rev Drug Discov; 2017 Mar; 16(3):155. PubMed ID: 28248932
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.
    Vos SJ; Verhey F; Frölich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Morbelli S; Frisoni GB; Drzezga A; Didic M; van Berckel BN; Simmons A; Soininen H; Kłoszewska I; Mecocci P; Tsolaki M; Vellas B; Lovestone S; Muscio C; Herukka SK; Salmon E; Bastin C; Wallin A; Nordlund A; de Mendonça A; Silva D; Santana I; Lemos R; Engelborghs S; Van der Mussele S; ; Freund-Levi Y; Wallin ÅK; Hampel H; van der Flier W; Scheltens P; Visser PJ
    Brain; 2015 May; 138(Pt 5):1327-38. PubMed ID: 25693589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and anti-HIV activity evaluation of novel 2,4-disubstituted 7-methyl-1,1,3-trioxo-2,4-dihydro-pyrazolo-[4,5-e][1,2]thiadiazines.
    Liu XY; Yan RZ; Wang Y; Zhan P; De Clercq E; Pannecouque C; Witvrouw M; Molina MT; Vega S
    Arch Pharm (Weinheim); 2008 Apr; 341(4):216-22. PubMed ID: 18266290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2,2,2-Trifluoroethyl-thiadiazines: a patent evaluation of WO2016023927.
    Dotsenko VV; Chigorina EA; Krivokolysko SG
    Expert Opin Ther Pat; 2016 Dec; 26(12):1371-1376. PubMed ID: 27785946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
    Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Grey matter atrophy in prodromal stage of dementia with Lewy bodies and Alzheimer's disease.
    Blanc F; Colloby SJ; Cretin B; de Sousa PL; Demuynck C; O'Brien JT; Martin-Hunyadi C; McKeith I; Philippi N; Taylor JP
    Alzheimers Res Ther; 2016 Jul; 8():31. PubMed ID: 27484179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.